



## ALX Oncology Announces Participation at Upcoming Investor Conferences

September 8, 2020

BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences in September:

### **Cantor Virtual Healthcare Conference**

Format: Fireside chat with Alethia Young, Director of Research

Date: Tuesday, September 15, 2020

Time: 1:20 PM Eastern Time

Webcast link: Available [here](#)

### **H.C. Wainwright 22<sup>nd</sup> Annual Global Investment Conference**

Format: Corporate Presentation

Date: Wednesday, September 16, 2020

Time: 2:30 PM Eastern Time

Webcast link: Available [here](#)

Company management will also be participating in one-on-one investor meetings at both conferences.

A live webcast of the events can also be accessed by visiting the Investors section of ALX Oncology's website at [www.alxoncology.com](http://www.alxoncology.com) and selecting the [Investor Calendar](#) under the "News & Events" tab. A replay of the webcasts will be archived for up to 90 days following the presentation dates.

### **About ALX Oncology**

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes and to continue clinical development for the treatment of a range of solid tumor indications.

Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 [peter@alxoncology.com](mailto:peter@alxoncology.com) Argot Partners (212)-600-1902 [alxoncology@argotpartners.com](mailto:alxoncology@argotpartners.com) Media Contact: Karen Sharma MacDougall (781) 235-3060 [alx@macbiocom.com](mailto:alx@macbiocom.com)